000 | 01949 a2200529 4500 | ||
---|---|---|---|
005 | 20250513160613.0 | ||
264 | 0 | _c19990301 | |
008 | 199903s 0 0 eng d | ||
022 | _a0027-8424 | ||
024 | 7 |
_a10.1073/pnas.96.1.133 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aFisher, J E | |
245 | 0 | 0 |
_aAlendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. _h[electronic resource] |
260 |
_bProceedings of the National Academy of Sciences of the United States of America _cJan 1999 |
||
300 |
_a133-8 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAlendronate _xpharmacology |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBone Resorption _xmetabolism |
650 | 0 | 4 |
_aCell Differentiation _xdrug effects |
650 | 0 | 4 | _aCells, Cultured |
650 | 0 | 4 |
_aCholesterol _xbiosynthesis |
650 | 0 | 4 |
_aClodronic Acid _xpharmacology |
650 | 0 | 4 |
_aDiterpenes _xpharmacology |
650 | 0 | 4 |
_aEnzyme Activation _xdrug effects |
650 | 0 | 4 |
_aFarnesol _xpharmacology |
650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xpharmacology |
650 | 0 | 4 |
_aLovastatin _xpharmacology |
650 | 0 | 4 |
_aMevalonic Acid _xmetabolism |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aOsteoclasts _xcytology |
650 | 0 | 4 |
_aProtein Kinases _xmetabolism |
650 | 0 | 4 | _aRabbits |
650 | 0 | 4 |
_aSkull _xmetabolism |
650 | 0 | 4 |
_aSqualene _xpharmacology |
700 | 1 | _aRogers, M J | |
700 | 1 | _aHalasy, J M | |
700 | 1 | _aLuckman, S P | |
700 | 1 | _aHughes, D E | |
700 | 1 | _aMasarachia, P J | |
700 | 1 | _aWesolowski, G | |
700 | 1 | _aRussell, R G | |
700 | 1 | _aRodan, G A | |
700 | 1 | _aReszka, A A | |
773 | 0 |
_tProceedings of the National Academy of Sciences of the United States of America _gvol. 96 _gno. 1 _gp. 133-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1073/pnas.96.1.133 _zAvailable from publisher's website |
999 |
_c9837167 _d9837167 |